Icahn Turns Up The Heat On Amylin, Urges Board To Sell
This article was originally published in The Pink Sheet Daily
Executive Summary
The activist investor, previously involved in buyouts at ImClone, Biogen Idec and Elan, as well as a proxy fight at Genzyme, scolds Amylin’s board for lack of transparency on purported Bristol offer and asserts the biotech is not positioned to maximize the market potential of Bydureon.
You may also be interested in...
The Orphan Drug Bubble
Two former biotech high flyers are up for sale, with Amylin attracting more would-be suitors than Human Genome Sciences. The spectacle of the bidding is great. But did you know that the orphan drug company Alexion is worth more than those two companies combined?
Lilly Diabetes R&D Center Arms Firm For Battle In China
Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.
New Diabetes R&D Center Arms Eli Lilly For Battle In China
Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.